PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer

Anubhav Dhull,Jing Wei,Anunay James Pulukuri,Anu Rani,Rishi Sharma,Nooshin Mesbahi,Hosog Yoon,Emily A. Savoy,Sylvia Xaiovong,Kenneth John Goody,C. E. Berkman,Jason Wu,Anjali Sharma,Sylvia Xaiovong Vi

DOI: https://doi.org/10.1039/d3nr06520k

IF: 6.7

2024-03-02

Nanoscale

Abstract:Prostate cancer (PCa) is the second leading cause of cancer-related deaths among men in the United States. Although early-stage treatments exhibit promising 5-year survival rates, the treatment options for advanced stage disease are constrained, with short survival benefits due to the challenges associated with effective and selective drug delivery to PCa cells. Even though targeting Prostate Specific Membrane Antigen (PSMA) has been extensively explored and is clinically employed for imaging and radio-ligand therapy, the clinical success of PSMA-based approaches for targeted delivery of chemotherapies remains elusive. In this study, we combine a generation 4 hydroxy polyamidoamine dendrimer (PD) with irreversible PSMA ligand (CTT1298) to develop a PSMA-targeted nanoplatform (PD-CTT1298) for selective intracellular delivery of potent chemotherapeutics to PCa. PD-CTT1298-Cy5 exhibits a PSMA IC50 in nanomolar range and demonstrates selective uptake in PSMA (+) PCa cells via PSMA mediated internalization. When systemically administered in a prostate tumor xenograft mouse model, PD-CTT1298-Cy5 selectively targets PSMA (+) tumors with significantly less accumulation in PSMA (-) tumors or upon blocking of the PSMA receptors. Moreover, the dendrimer clears rapidly from the off-target organs limiting systemic side-effects. Further, the conjugation of anti-cancer agent, cabozantinib to PSMA-targeted dendrimer translates to a significantly enhanced anti-proliferative activity in vitro compared to the free drug. These findings highlight the potential of PD-CTT1298 nanoplatform as a versatile approach for selective delivery of high payloads of potent chemotherapeutics to PCa, where dose related systemic side-effects are a major concern.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology,chemistry